In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.

Br J Cancer

Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp (UIA/UZA), Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium.

Published: December 2003

Ecteinascidin 743 (ET-743) is a new marine-derived agent with promising activity against a number of solid tumours. In four human tumour cell lines, the interaction between ET-743 and radiation was investigated in relation to the effects of ET-743 on the cell cycle, in vitro. Cell survival was measured based on quantitative staining of cellular protein by sulforhodamine B. A 24 h treatment with ET-743 before radiation resulted in a moderate increase in radiosensitivity in three out of four cell lines. Dose enhancement factors > or =1.8 were observed for concentrations resulting in 52, 46 and 30% cell kill in ECV304, H292 and CAL-27, respectively, whereas in A549 no radiosensitisation was observed (no significant increase in radiosensitivity). According to the combination index analysis, synergism was observed only in ECV304 and CAL-27 cells. A 24 h incubation with ET-743 resulted in a concentration-dependent G2/M block, which might explain the moderate radiosensitising effects in ECV304 and H292. The lack of radiosensitisation in A549 might be due to the S phase delay preceding the G2/M block at the moment of radiation, which only occurred in this cell line. In conclusion, ET-743 has moderate cell line-dependent radiosensitising properties; however, only when cytotoxic concentrations of ET-743 are used. In one of the four cell lines tested, no radiosensitisation was observed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395275PMC
http://dx.doi.org/10.1038/sj.bjc.6601431DOI Listing

Publication Analysis

Top Keywords

et-743 radiation
12
cell lines
12
cell
9
ecteinascidin 743
8
et-743
8
743 et-743
8
cell cycle
8
et-743 cell
8
increase radiosensitivity
8
ecv304 h292
8

Similar Publications

(1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare and have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed to evaluate the real-life effectiveness and safety of trabectedin.

View Article and Find Full Text PDF
Article Synopsis
  • * A case study describes a 65-year-old woman with stage 1B LMS who initially underwent surgery and chemotherapy but faced multiple recurrences over 9 years, leading to a second-line treatment with doxorubicin and trabectedin.
  • * The patient responded well to the second-line therapy, achieving partial remission after 6 cycles and maintaining stable disease for a total of 16 months of progression-free
View Article and Find Full Text PDF

Traditional methods of treating lung cancer have not been very effective, contributing to the disease's high incidence and death rate. As a result, Fn/Tn-PLGA NPs, a novel directed fucoidan and trabectedin complex loaded PLGA nanoparticle, were produced to investigate the role of developing therapeutic strategies for NSCLC and A549 cell lines. Quantitative real-time polymerase chain reaction was used to examine protein expression and mRNA expression, respectively.

View Article and Find Full Text PDF

Background And Objectives: Dimensional response is an unmet need in second lines of advanced soft tissue sarcomas (STS). Indeed, the three approved drugs, pazopanib, trabectedin, and eribulin, achieved an overall response rate (ORR) of less than 10%. This fact potentially hinders the options for fast symptomatic relief or surgical rescue.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!